Skip to main content

Table 5. Completed clinical trials of Akt inhibitors in OC

From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

Phase

Treatment

No. of OC patients

Selected toxicities

Efficacy

Reference

I

Perifosine (MTD = 150 mg/day) + docetaxel

21

Nausea, vomiting, anorexia, and fatigue

At MTD in 11 patients, PR in 1 PTEN-null patient, SD in 3 patients

Fu et al.[37]

I

GSK795 (25, 50, or 75 mg/day)

12

Grade 2 anorexia (18%) and vomiting (18%)

2 (16%) cases of SD for 6 months with tumor shrinkage of 26% and 11%, respectively

Gungor et al.[38]

I

GSK211 (50–150 mg/day) + carboplatin (AUC = 5) + paclitaxel (175 mg/m2)

29

Grade 1/2 diarrhea, nausea, and fatigue

All patients in dose escalation: ORR = 30%; At MTD: ORR = 50%

Blagden et al.[39]

At MTD: ORR = 50%

  1. MTD, maximal tolerated dose; AUC, area under curve; SD, stable disease; ORR, objective response rate.